Bendamustine and Plerixafor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bendamustine (bendamustine) and Plerixafor (plerixafor). Common drug interactions include malignant neoplasm progression among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Bendamustine and Plerixafor. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Bendamustine?

Bendamustine has active ingredients of bendamustine. eHealthMe is studying from 9,508 Bendamustine users. Check the latest studies of Bendamustine.

What is Plerixafor?

Plerixafor has active ingredients of plerixafor. eHealthMe is studying from 694 Plerixafor users. Check the latest studies of Plerixafor.

On Jul, 12, 2026

13 people who take Bendamustine and Plerixafor together, and have interactions are studied.

Bendamustine and Plerixafor drug interactions.

What are the common drug interactions of Bendamustine and Plerixafor, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Therapeutic response decreased (less preventive response)
Disease progression
Natural killer-cell lymphoblastic lymphoma (cancer tumour of blood cell)
T-cell lymphoma (a blood cell cancer)

male:

Drug ineffective
Stress
Lymphoma (cancer that begins in immune system cells)
Mucosal inflammation (infection of mucous membrane)
Odynophagia (painful swallowing, in the mouth (oropharynx) or oesophagus)
Inflammation
Malignant neoplasm progression (cancer tumour came back)
Nausea (feeling of having an urge to vomit)
Plasmablastic lymphoma (aggressive b-cell cancer occurring mainly in the jaws and oral cavity)
Pyrexia (fever)

What are the common drug interactions of Bendamustine and Plerixafor, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Therapeutic response decreased (less preventive response)
Inflammation
Nausea (feeling of having an urge to vomit)
Plasmablastic lymphoma (aggressive b-cell cancer occurring mainly in the jaws and oral cavity)
Pyrexia (fever)
Stomatitis (inflammation of mucous membrane of mouth)
Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)
Malignant neoplasm progression (cancer tumour came back)

40-49:

Cystitis viral (inflammation of the wall of the bladder by virus)
Mucosal inflammation (infection of mucous membrane)
Odynophagia (painful swallowing, in the mouth (oropharynx) or oesophagus)

50-59:

Drug ineffective
Stress
Disease progression
Natural killer-cell lymphoblastic lymphoma (cancer tumour of blood cell)
T-cell lymphoma (a blood cell cancer)

60+:

Lymphoma (cancer that begins in immune system cells)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 4 people, 30.77%
Hodgkin's Lymphoma (cancer originating from white blood cells): 3 people, 23.08%
Haematopoietic Stem Cell Mobilisation: 3 people, 23.08%
Bone Marrow Conditioning Regimen: 3 people, 23.08%
Blood Stem Cell Harvest: 3 people, 23.08%
Hodgkin's Disease Mixed Cellularity Stage Iv (cancer originating from white blood cells- stage iv): 2 people, 15.38%
Urination - Excessive Volume: 1 person, 7.69%
T-Cell Lymphoma (a blood cell cancer): 1 person, 7.69%
Plasmablastic Lymphoma (aggressive b-cell cancer occurring mainly in the jaws and oral cavity): 1 person, 7.69%
Natural Killer-Cell Lymphoblastic Lymphoma (cancer tumour of blood cell): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Bendamustine and Plerixafor?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously